fbpx
Header Image

Identifying Patients at Risk of Opioid Abuse, Miss-use, or Diversion

  1. Dosing guidelines
  2. Indications and contraindications for prescribing
  3. Best practices for testing and monitoring

 

Additional Reading

  • Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC guideline for prescribing opioids for chronic pain—United States, 2016. Jama315(15), 1624-1645.
  • Starrels, J. L., Becker, W. C., Alford, D. P., Kapoor, A., Williams, A. R., & Turner, B. J. (2010). Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Annals of internal medicine152(11), 712-720.
  • Manchikanti, L., Manchukonda, R., Pampati, V., Damron, K. S., Brandon, D. E., Cash, K. A., & McManus, C. D. (2006). Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids?. Pain Physician9(2), 123.
  • Baxter Sr, L., Brown, D. L., Hurford, D. M., Jacobs, W., Kleinschmidt, K., Kushner, M., … & Wiegand, T. (2017). Appropriate Use of Drug Testing in Clinical Addiction Medicine.

March 1 @ 11:00

11:00 am

– 11:45 am

(45′)

Classroom

Gail McGlothlen, DNP, RN